Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]
Hetta HF +14 more
europepmc +1 more source
A retrospective analysis of outpatient use of small-molecule targeted inhibitors for lymphoma across six regions of China (2016-2022). [PDF]
Chen B +8 more
europepmc +1 more source
TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]
Niemann CU.
europepmc +1 more source
Platelet Rubicon Bidirectional Regulation of GPVI and Integrin αIIbβ3 Signaling Mitigates Stroke Infarction Without Compromising Hemostasis. [PDF]
Chen X +11 more
europepmc +1 more source
Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. [PDF]
Mushtaq A +10 more
europepmc +1 more source
Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence. [PDF]
Dirican CD +7 more
europepmc +1 more source
Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. [PDF]
Wang J +6 more
europepmc +1 more source
Purulent meningitis in X-linked agammaglobulinemia: one case report. [PDF]
Ba A +5 more
europepmc +1 more source

